Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageOrganon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $398.0MThe company’s own SEC segment disclosure.
- Nexplanon Implanon NXT$129.0M32%
- Hadlima$55.0M14%
- Renflexis$44.0M11%
- Vtama$34.0M9%
- Dulera$30.0M8%
- Follistim AQ$17.0M4%
- Other (17)$89.0M22%
Organon & Co. (OGN) reported revenue of $1.56B in Q2 2026 (quarter ended June 30, 2026), down 2.3% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $108M (6.9% of revenue). For the full year FY2025, revenue was $6.22B (−2.9% year on year) and net income $187M. Its largest product in 2026-Q2 was Nexplanon Implanon NXT at $129M, 32% of the disclosed total, just ahead of Hadlima at 14%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
Ranks #16 of 16 by Smart Score